Tang Capital Management’s ADMA Biologics ADMA Stock Holding History

Tang Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,050,000	Closed	-$15.4M	–	78
2025 Q3	$15.4M	Hold	1,050,000	–	–	0.59%	44
2025 Q2	$19.1M	Hold	1,050,000	–	–	0.97%	32
2025 Q1	$20.8M	Buy	1,050,000 +500,000	+91%	+$8.65M	1.15%	24
2024 Q4	$9.43M	Buy	+550,000	New	+$10.3M	0.62%	45
2024 Q1	–	Sell	-1,360,000	Closed	-$6.15M	–	101
2023 Q4	$6.15M	Hold	1,360,000	–	–	0.57%	43
2023 Q3	$4.87M	Buy	1,360,000 +100,000	+8%	+$385K	0.69%	44
2023 Q2	$4.65M	Buy	+1,260,000	New	+$4.67M	0.68%	38
2022 Q4	–	Sell	-992,840	Closed	-$2.41M	–	90
2022 Q3	$2.41M	Buy	+992,840	New	+$2.38M	0.3%	67

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Tang Capital Management's ADMA Position: Q4 2025 in Review

Tang Capital Management sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 1,050,000 shares — an estimated $15.4M sold.

Tang Capital Management first reported a position in ADMA in Q3 2022 and held it in 8 quarters. The position peaked at $20.8M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

Tang Capital Management reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 1,050,000 ADMA Biologics shares in Q4 2025, an estimated $15.4M.
Tang Capital Management first reported a position in ADMA Biologics in Q3 2022 and held it in 8 quarters.
Tang Capital Management's ADMA Biologics position peaked at $20.8M in Q1 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.